Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring: Prospective Health-economic Evaluation in Patients in Remission With Atypical Hemolytic Uraemic Syndrome Requiring Long-term Treatment.

NCT04859608 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT04859608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring: Prospective Health-economic Evaluation in Patients in Remission With Atypical Hemolytic Uraemic Syndrome Requiring Long-term Treatment.
Lead sponsor
University Hospital, Tours
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2021
Completion date
December 28, 2023
Enrollment
40 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hemolytic-uremic syndrome, atypical